Connect with us

Emerging Markets

Trans Global Group, Inc. (OTC: TGGI) Breakout into Copper Land as Reverse Merger Runner Awaits Imminent 8k

Published

on

Trans Global Group, Inc. (OTC: TGGI) is making a highly explosive move up the charts in recent days since once again reversing off support levels with power. We noted in our last article on TGGI that the stock was “drifting towards support level of $0.007” we suspected it would hold and it did not just hold support, it moved up with power averaging well over $400,000 a day in dollar volume as it rocketed up into penny land while the overall markets sank. Investors are looking for a move over $0.0298 and a breakout into a whole new dimension just like RM play TSNP did a year and a half ago. TGGI is a fully reporting reverse merger play with global ambitions and a massive investor following that is only growing bigger. Mr. Chen Ren Feiyang currently owns the controlling block of TGGI and along with TGGI president, Mr. Tang Jiacheng the two have long been very public about their intentions for going to a national market and forming a global enterprise.   

TGGI is one of the most bashed stocks in small caps and as we have said many times before based on years of experience in microcaps; some of the most bashed stocks I ever saw were the ones that made the biggest runs of all. Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars including TSNP/HMBL which we first reported on at $0.003. TGGI investors are waiting for the 8k to drop which could come at any time, an event that could easily triple the market cap of TGGI in hours considering the enormous following this stock has. For now, TGGI is doing just fine without the 8k and the magic tipping point – $0.0298 is not far from here considering the strength and power with which TGGIis running northbound now. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Trans Global Group Inc (OTCMKTS: TGGI) is a Delaware holding company that plans to conduct substantially all of its operations and business in China through PRC based subsidiaries. On April 29, 2021, ONE DAY after the HK requirements for filings (SURGICAL) Chen Ren executed the Change of Control documents for $TGGI. In it, they stated CLEAR intentions to acquire liquor companies in China. Chen Ren is now the controlling shareholder of TGGI having purchased control for $150,000. Another important figure in TGGI is President, Mr. Tang Jiacheng who along with Chen Ren has long stated his intentions for forming a global enterprise and listing on the NASDAQ stock exchange. 

TGGI has an enormous following and among the largest in small caps, this tweet sums it up perfectly:

Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and many RM stocks, we have covered on this website have gone from pennies to dollars. Two recent RM runners that stand out are TSNP which went from sub pennies (where we first wrote about it) to over $6 per share after the ticker change to HMBL. We also covered HRBR reverse merger with Air Wisconsin Airlines on Microcapdaily when the stock was a few cents before it skyrocketed to over $3. Once thing that TGGI has going for it is an SEC filer and virtually debt free and the stock could very well be trading on the OTCQB before long, a move that could triple the market valuation overnight. 

  To Find out the inside Scoop on TGGI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

 

TGGI

https://twitter.com/TraderDLM/status/1544668531475812352

 

TGGI ambitious new CEO and controlling shareholder of the Company Chen Ren is the founder and owner of Zuixiangui wines which produces over 4,000 tons (11M 1 Liter bottles) annually using patented methods of production on an operations site of more than 300 acres. It is expected that Zuixiangui wines will reverse merge into TGGI. Chen’s passion for wine matched his dreams of becoming a public company and he has made clear his intentions to one day list TGGI on the big boards.  

Chen Ren was a famous singer/entertainer in his earlier years. Amongst his many songs/albums, he made numerous songs about wine. He dreamed of making a specific wine and sharing it with the world. Chen’s passion for wine matched his dreams of becoming a NASDAQ company and he has made clear his intentions to one day list TGGI on the big boards. Mr. Ren is the founder and owner of Zuixiangui wines which produces over 4,000 tons (11M 1 Liter bottles) annually using patented methods of production on an operations site of more than 300 acres. It is expected that Zuixiangui wines will reverse merge into TGGI. Zuixiangui has also been making some big moves recently Shaanxi Seeds and Hunan Pharmaceuticals both established business in China. They also announced an incredibly strategic and exciting contract with Yijulian E-commerce Co. TGGI is authorized to issue 12,000,000,000 shares of common stock with a par value of $0.0001 per share. As of December 31, 2021, 8,665,578,306 shares were issued and outstanding. 

Zuixiangui is an up-and-coming potential leader in this space in China and rumors continue to abound that Zuixiangui International Holdings Group will reverse merger into the TGGI shell. The company’s intent to gain access to US capital markets is highlighted in numerous articles, which states that Zuixiangui has already started the listing process and is preparing to go public on the Nasdaq stock exchange. Ren Feiyang is the Chairman of the Board of both Trans Global Group and Zuixiangui International Holdings Group and he is also the controlling shareholder of TGGI. For a more detailed look at what is currently happening with TGGI check out our last article here. 

For More on TGGI Subscribe Right Now!

TGGI is the biggest pending Reverse Merger (RM) play in small caps that is currently making a powerful run into copper land following a final test of support levels. Over the past few months TGGI has amassed an enormous investors following and is once again emerging as a volume leader in small caps easily topping $400,000 in dollar volume per day. Investors are looking for a move over $0.0298 and a breakout into a whole new dimension just like RM play TSNP did a year and a half ago. TGGI has a lot of bashers putting in overtime begging investors to sell under a penny last week but few listened. They have tried everything to discredit the Company yet their presence and persistence gives away their real motives here. As I keep saying based on many years of experience in microcaps, some of the most bashed stocks I ever saw were the ones that made the biggest runs of all. TGGI is a lotto play and anything is liable to happen here but the stock looks very strong and by the looks of it, this is just the very beginning as we await the imminent 8k which could propel TGGI into a whole new dimension. We will be updating on TGGI when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in TGGI either long or short and we have not been compensated for this article

Emerging Markets

Is today’s surge in MMTec Inc (NASDAQ: MTC) justified ?

Published

on

MMTec, Inc. (NASDAQ: MTC) ended the day at $2.0700 with a gain of $0.5800 (+38.93%). The stock prices fluctuated between $1.4000 - $2.5299, with more than 2.98M shares exchanging hands.

MMTec, Inc. (NASDAQ: MTC) ended the day at $2.0700 with a gain of $0.5800 (+38.93%). The stock prices fluctuated between $1.4000 – $2.5299, with more than 2.98M shares exchanging hands.

So why did MTC surge today ?

The failure of Silicon Valley Bank led to a sell-off in equities and a shift to safe-haven assets, such as US Treasuries and gold. Markets have calmed down somewhat, and the worst of the equity sell-off seems to be over. However, the market anticipates that the markets will be somewhat uneasy until a better understanding of inflation is reached and what the Federal Reserve will do next week.

To Find out the inside Scoop on MTC, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Despite most investors currently avoiding the banking sector, Wall Street sees potential opportunities, particularly in regional banks. The chaos in the market has created opportunities in the industry and several banking stocks are being punished just for being a banking stock. The collapse of Silicon Valley Bank was due to its specialisation in venture-capital financing, which made it vulnerable to the higher interest rate regime of the past 12 months.

For more on MTC Subscribe Right Now!

Therfore, today’s gains in MTC seems to be more a sympathy bounce considering the overall banking sector. Earlier in March, MMTEC, Inc. (Nasdaq: MTC) declared that it will relocate its operations from Beijing to the Hong Kong Special Administrative Region, effective March 6, 2023. The Company’s subsidiary, MM Future Technology Limited, which is a Hong Kong incorporated limited company, will assume all operations previously conducted by its subsidiary, Gujia (Beijing) Technology Co., Ltd. However, Gujia will continue to carry out specific technical research and development functions. Further, the Company, through its subsidiary HC Securities (HK) Limited, and other entities, will continue to invest its human resources in asset management and securities underwriting, and other related businesses, aiming to attract global funds to invest in the Chinese market and support China’s economic growth. The Company’s new operations headquarters is located at Room 2302, 23rd Floor, FWD Financial Center, 308 Des Voeux Road Central, Sheung Wan, Hong Kong.

We will be updating on MTC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MTC.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have no position in MTC and have not been compensated for this article.

Continue Reading

Emerging Markets

Cazoo Group Ltd (CZOO) is one stock that Wall Street could be talking for day to come

Published

on

Cazoo Group Ltd (NASDAQ: CZOO) last traded at $2.62, a gain of +0.6400 (+32.32%). More than 5M shares exchanged hands compared to an average daily volume of 228K shares. Considering that the 52 week high of CZOO is more than 65$, there seems to be a lot of room to the upside.

To Find out the inside Scoop on CZOO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Why did CZOO surge last week? Welcome to the Carvana of the UK!

Cazoo, a publicly traded company (NYSE: CZOO), was founded in 2018 by serial entrepreneur Alex Chesterman OBE. The company’s mission is to revolutionize the UK’s car buying and selling experience by offering consumers better selection, value, transparency, convenience, and peace of mind. Cazoo’s goal is to make the car buying or selling process as simple as purchasing any other product online. The company enables customers to buy, sell, or finance a car entirely online, with delivery or collection available in as little as 72 hours.

Recently, Cazoo Group Ltd, the UK’s leading online car retailer, updated its business performance and progress with the restructuring announced in January. The CEO, Alex Chesterman, expressed satisfaction with the progress made so far in 2023, despite the challenging economic environment. The company has taken swift and decisive management action to restructure the group, improve unit economics, and reduce fixed costs. The rightsizing of headcount and operational footprint is well underway, and the company expects to complete the restructuring before the end of Q1 2023. The company has seen significant improvement in its GPU, with retail GPU tracking at approximately £900, up from £600 in Q4 2022. Cazoo has sold over 100,000 cars entirely online in the UK in the three years since its launch. The company remains fully focused on driving higher profitability and has appointed Jonathan Dunkley as Chief Operating Officer. Cazoo’s cash reserves remain strong, and the company expects to achieve profitability without external funding until H2 2024. The company expects to end 2023 with over £100m of cash and cash equivalents on its balance sheet and sell 40,000-50,000 UK retail units in the current year.

For more on CZOO, Subscribe Right Now!

The online car market in the UK has been growing rapidly in recent years, driven by increasing consumer demand for convenience and transparency in the car buying process. Online car retailers such as Cazoo, Carzam, and Cinch have emerged as major players in the market, offering a wide selection of used cars for sale online with home delivery or pickup options. These companies use advanced technology to provide customers with a seamless buying experience, including virtual vehicle inspections, transparent pricing, and easy financing options. The COVID-19 pandemic has further accelerated the shift towards online car buying as consumers seek to avoid in-person interactions and dealerships adapt to new ways of doing business.

So if CZOO learns from Carvana’s mistake, there is little to no doubt that CZOO could be the talk of the town in days to come. We will be updating on CZOO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CZOO.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CZOO, either long or short, and we have not been compensated for this article

Continue Reading

Emerging Markets

Ocean Biomedical Stock Surge could just be getting started and here’s why

Published

on

Shares of Ocean Biomedical (NASDAQ:OCEA) surged more than 100% on Thursday, following a talk by the company’s scientific co-founder, Dr. Jack A. Elias, at Brown University’s Legorreta Cancer Center. The preclinical-stage biotech, which went public on the NASDAQ on February 15, focuses on developing novel treatments for deadly diseases, including malaria, multiple cancers, and pulmonary fibrosis.

During the talk, Dr. Elias presented exciting details about potential therapies to suppress tumors in various cancers, focusing on the company’s work in understanding the role of the protein Chitinase 3-like-1 (CHI3LI) in the progression of lung cancer. He also discussed his discoveries on how certain monospecific and bispecific antibodies can be used as therapies to treat non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). The company aims to expedite these findings into phase 1 trials.

To Find out the inside Scoop on OCEA, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The excitement over this preliminary news stems from the large target groups for both diseases. According to Cancer.net statistics, NSCLC is the leading cause of cancer death and the second-most diagnosed cancer in the US, affecting around 236,740 people. GBM is the most common primary brain tumor in adults, with an average survival period of just 15 months and no cure.

The recent surge in Ocean Biomedical’s shares also comes on the heels of an announcement on February 28 that co-founder Dr. Jonathan Kurtis had been awarded a patent for the discovery of the third parasite target PfCDPK-5. This target has the potential to be used to halt the malaria parasite in various stages of its cycle, opening up new possibilities for treating this deadly disease.

Ocean Biomedical’s focus on developing novel treatments for deadly diseases and its recent exciting findings have generated significant investor interest. However, it is important to note that investing in preclinical-stage biotech companies carries a high level of risk. There is no guarantee that these discoveries will translate into effective treatments or that the company will receive regulatory approval.

For more on OCEA Subscribe Right Now!

Nevertheless, the positive developments from Ocean Biomedical are a significant milestone and hold great promise for patients suffering from deadly diseases such as cancer and malaria. If the company’s discoveries prove successful in further clinical trials, they could potentially generate significant revenue and transform the standard of care for these diseases. We will be updating on OCEA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OCEA.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in OCEA, either long or short, and we have not been compensated for this article

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.